Non-metastatic Prostate Cancer Clinical Trial
Official title:
A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT00673205 -
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
|
Phase 3 | |
| Completed |
NCT00672282 -
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT01317043 -
A Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy
|
Phase 2 | |
| Completed |
NCT06204302 -
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
|
||
| Completed |
NCT00239291 -
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06202248 -
A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer
|
N/A | |
| Recruiting |
NCT04049747 -
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
|
N/A | |
| Active, not recruiting |
NCT05617885 -
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
|
Phase 1/Phase 2 |